Wolfgang Köhler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wolfgang Köhler has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
F. Hoffmann
Department of Neurology General Hospital Martha‐Maria Halle‐Dölau Germany
3 shared publicationsA. Kraft
Department of Neurology General Hospital Martha‐Maria Halle‐Dölau Germany
2 shared publicationsH. Topka
Department of Neurology General Hospital Bogenhausen Munich Germany
2 shared publicationsR. Klingel
Apheresis Research Institute Cologne Germany
2 shared publicationsS. Ehrlich
Department of Neurology and Neurological Intensive Care Medicine Fachkrankenhaus Hubertusburg Wermsdorf Germany
2 shared publicationsA. Apel-Neu
Klinik für Neurologie, Universität Rostock, Rostock, Deutschland
1 shared publication
Latest Publications
- 3 March 2014
- Published by Wiley in European Journal of Neurology
- Vol. 22 (1) , 203-206
Tryptophan immunoadsorption for the treatment of autoimmune encephalitis
Background and purpose: Detection of autoantibodies against neuronal surface antigens and their correlation with the pattern and severity of symptoms led to the definition of new autoimmune‐mediated forms of encephalitis and was essential for the initiation of immunotherapies including plasma exchange. The elimination of autoantibodies using selective immunoadsorption (IA) is a pathophysiologically guided therapeutic approach but has not yet been evaluated in a separate analysis.Methods: A retrospective analysis was performed of patients with autoimmune encephalitis who were treated with tryptophan IA in six neurological clinics between 2009 and 2013. The modified Rankin scale (mRS) was used to evaluate neurological status before and after IA.Results: Data on 13 patients were documented. Twelve patients were positive for specific autoantibodies (NMDA‐R, GABA, GAD, Lgl1). Patients received a series of a median of six IA treatments. Median mRS of all patients was 3.0 before IA and 2.0 after IA (P < 0.001). Eleven patients improved by at least one point in mRS after IA.Conclusion: For autoimmune‐mediated forms of encephalitis rapid elimination of autoantibodies with selective IA seems to be an effective therapeutic option as part of multimodal immune therapy.
- 3 March 2014
- Published by Wiley in European Journal of Neurology
- Vol. 22 (1) , 203-206
Tryptophan immunoadsorption for the treatment of autoimmune encephalitis
Background and purpose: Detection of autoantibodies against neuronal surface antigens and their correlation with the pattern and severity of symptoms led to the definition of new autoimmune‐mediated forms of encephalitis and was essential for the initiation of immunotherapies including plasma exchange. The elimination of autoantibodies using selective immunoadsorption (IA) is a pathophysiologically guided therapeutic approach but has not yet been evaluated in a separate analysis.Methods: A retrospective analysis was performed of patients with autoimmune encephalitis who were treated with tryptophan IA in six neurological clinics between 2009 and 2013. The modified Rankin scale (mRS) was used to evaluate neurological status before and after IA.Results: Data on 13 patients were documented. Twelve patients were positive for specific autoantibodies (NMDA‐R, GABA, GAD, Lgl1). Patients received a series of a median of six IA treatments. Median mRS of all patients was 3.0 before IA and 2.0 after IA (P < 0.001). Eleven patients improved by at least one point in mRS after IA.Conclusion: For autoimmune‐mediated forms of encephalitis rapid elimination of autoantibodies with selective IA seems to be an effective therapeutic option as part of multimodal immune therapy.
- Open Access
- 1 January 2014
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 18
Language and cognition in children with metachromatic leukodystrophy: onset and natural course in a nationwide cohort
Metachromatic leukodystrophy (MLD) is a rare, genetic neurodegenerative disease. It leads to progressive demyelination resulting in regression of development and early death. With regard to experimental therapies, knowledge of the natural course of the disease is highly important. We aimed to analyse onset and character of first symptoms in MLD and to provide detailed natural course data concerning language and cognition.
- 1 January 2014
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 18
Open AccessLanguage and cognition in children with metachromatic leukodystrophy: onset and natural course in a nationwide cohort
Metachromatic leukodystrophy (MLD) is a rare, genetic neurodegenerative disease. It leads to progressive demyelination resulting in regression of development and early death. With regard to experimental therapies, knowledge of the natural course of the disease is highly important. We aimed to analyse onset and character of first symptoms in MLD and to provide detailed natural course data concerning language and cognition.
- 1 December 2013
- Published by Georg Thieme Verlag KG in Dialyse aktuell
- Vol. 17 (10) , 544-548
Autoantikörperassoziierte Erkrankungen des zentralen Nervensystems – Neue Indikationen der Immunadsorption
Unmittelbare Antikörperelimination, Umverteilungspuls (d. h., der rasch induzierte Konzentrationsgradient zwischen intravasalem und extravasalem Verteilungsraum) und Immunmodulation sind die prinzipiellen Wirkmechanismen der therapeutischen Apherese, das heißt von Plasmaaustausch (PA) und Immunadsorption (IA) bei neurologischen Autoimmunerkrankungen. Die therapeutische Apherese wird zur raschen Remission schwerer akuter neurologischer Symptome eingesetzt, aber auch zur langfristigen Rehabilitation klinischer Verläufe, bei denen die medikamentöse Therapie unzureichend anspricht oder durch Nebenwirkungen limitiert wird. PA oder IA sind in diesen Situationen Teil einer multimodalen oder eskalierenden immunologisch ausgerichteten Therapie in Kombination oder alternativ zu intravenös applizierten Immunglobulinen, Steroiden oder dem gesamten Spektrum der Immunsuppressiva und Biologika. Die selektive IA ersetzt zunehmend den unselektiven PA aufgrund der höheren Therapiesicherheit und der zunehmenden Kenntnis über die pathophysiologische Relevanz von Autoantikörpern. Jüngste Erfolge bei autoimmunen Erkrankungen des ZNS wie Multiple Sklerose (MS), Neuromyelitis optica (NMO) und autoimmune Enzephalitiden haben dieses Konzept bestätigt und Eingang in die aktuellen Leitlinien der Deutschen Gesellschaft für Neurologie (DGN) gefunden. Immediate antibody elimination, pulsed induction of antibody redistribution and immunomodulation are major forces of efficacy of therapeutic apheresis, i. e. plasma exchange (PE) or immunoadsorption (IA) for autoimmune neurologic disorders. Therapeutic apheresis can offer rapid response for severe acute neurologic symptoms and stable rehabilitation in long-term clinical courses being refractory to drug-based strategies or complicated by drug side effects. PE or IA in these situations must be considered as part of multimodal or escalating immune treatment strategies in combination or in competition with intravenously administered immunoglobulins, corticosteroids, the full spectrum of immunosuppressive drugs and biologicals. Selective IA is increasingly replacing PE due to its superior safety profile and increasing knowledge on pathogenic relevance of autoantibodies. Recent experiences in autoimmune diseases of the central nervous system, e. g. multiple sclerosis, neuromyelitis optica and autoimmune encephalitis, confirmed this concept and have become part of the guidelines of the German Society of Neurology.
- 1 December 2013
- Published by Georg Thieme Verlag KG in Dialyse aktuell
- Vol. 17 (10) , 544-548
Autoantikörperassoziierte Erkrankungen des zentralen Nervensystems – Neue Indikationen der Immunadsorption
Unmittelbare Antikörperelimination, Umverteilungspuls (d. h., der rasch induzierte Konzentrationsgradient zwischen intravasalem und extravasalem Verteilungsraum) und Immunmodulation sind die prinzipiellen Wirkmechanismen der therapeutischen Apherese, das heißt von Plasmaaustausch (PA) und Immunadsorption (IA) bei neurologischen Autoimmunerkrankungen. Die therapeutische Apherese wird zur raschen Remission schwerer akuter neurologischer Symptome eingesetzt, aber auch zur langfristigen Rehabilitation klinischer Verläufe, bei denen die medikamentöse Therapie unzureichend anspricht oder durch Nebenwirkungen limitiert wird. PA oder IA sind in diesen Situationen Teil einer multimodalen oder eskalierenden immunologisch ausgerichteten Therapie in Kombination oder alternativ zu intravenös applizierten Immunglobulinen, Steroiden oder dem gesamten Spektrum der Immunsuppressiva und Biologika. Die selektive IA ersetzt zunehmend den unselektiven PA aufgrund der höheren Therapiesicherheit und der zunehmenden Kenntnis über die pathophysiologische Relevanz von Autoantikörpern. Jüngste Erfolge bei autoimmunen Erkrankungen des ZNS wie Multiple Sklerose (MS), Neuromyelitis optica (NMO) und autoimmune Enzephalitiden haben dieses Konzept bestätigt und Eingang in die aktuellen Leitlinien der Deutschen Gesellschaft für Neurologie (DGN) gefunden. Immediate antibody elimination, pulsed induction of antibody redistribution and immunomodulation are major forces of efficacy of therapeutic apheresis, i. e. plasma exchange (PE) or immunoadsorption (IA) for autoimmune neurologic disorders. Therapeutic apheresis can offer rapid response for severe acute neurologic symptoms and stable rehabilitation in long-term clinical courses being refractory to drug-based strategies or complicated by drug side effects. PE or IA in these situations must be considered as part of multimodal or escalating immune treatment strategies in combination or in competition with intravenously administered immunoglobulins, corticosteroids, the full spectrum of immunosuppressive drugs and biologicals. Selective IA is increasingly replacing PE due to its superior safety profile and increasing knowledge on pathogenic relevance of autoantibodies. Recent experiences in autoimmune diseases of the central nervous system, e. g. multiple sclerosis, neuromyelitis optica and autoimmune encephalitis, confirmed this concept and have become part of the guidelines of the German Society of Neurology.
- 18 January 2013
- Published by Springer Nature in Der Nervenarzt
- Vol. 84 (4) , 498-507
Therapeutische Apherese bei autoimmuner Enzephalitis
The correlation between detection of autoantibodies and the pattern and severity of symptoms in patients with encephalitis was the crucial factor for the initiation of immune therapy. The elimination of autoantibodies using therapeutic apheresis by plasma exchange (PE) and immunoadsorption (IA) is a pathophysiologically guided therapeutic approach. The aim was to evaluate the current use of PE and for the first time also of IA for patients with autoimmune encephalitis. A nationwide data collection was performed and the modified Rankin score (mRS) was used to evaluate the severity of neurological symptoms. Data of 31 treatment courses (30 patients and 1 relapse) were documented and 22 patients were positive for autoantibodies (NMDA-R, GABA, VGKC, Hu). In 23 cases PA was performed, tryptophan IA in 7 cases and in 1 patient both methods were applied. In 67 % of the treatment courses the mRS improved and the mean mRS of all patients was 3.2 before apheresis and 2.2 after apheresis (p < 0.05). All patients who were treated with IA improved clinically from a mean mRS of 3.9 before IA to 1.9 after IA (p < 0.01). For immune-mediated forms of encephalitis rapid elimination of autoantibodies with PA and IA seems to be an effective therapeutic option as part of a multimodal immune therapy and is already established in many clinics in Germany.
- 18 January 2013
- Published by Springer Nature in Der Nervenarzt
- Vol. 84 (4) , 498-507
Therapeutische Apherese bei autoimmuner Enzephalitis
The correlation between detection of autoantibodies and the pattern and severity of symptoms in patients with encephalitis was the crucial factor for the initiation of immune therapy. The elimination of autoantibodies using therapeutic apheresis by plasma exchange (PE) and immunoadsorption (IA) is a pathophysiologically guided therapeutic approach. The aim was to evaluate the current use of PE and for the first time also of IA for patients with autoimmune encephalitis. A nationwide data collection was performed and the modified Rankin score (mRS) was used to evaluate the severity of neurological symptoms. Data of 31 treatment courses (30 patients and 1 relapse) were documented and 22 patients were positive for autoantibodies (NMDA-R, GABA, VGKC, Hu). In 23 cases PA was performed, tryptophan IA in 7 cases and in 1 patient both methods were applied. In 67 % of the treatment courses the mRS improved and the mean mRS of all patients was 3.2 before apheresis and 2.2 after apheresis (p < 0.05). All patients who were treated with IA improved clinically from a mean mRS of 3.9 before IA to 1.9 after IA (p < 0.01). For immune-mediated forms of encephalitis rapid elimination of autoantibodies with PA and IA seems to be an effective therapeutic option as part of a multimodal immune therapy and is already established in many clinics in Germany.
- 1 June 2010
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 23 (3) , 234-241
Leukodystrophies with late disease onset: an update
Knowledge of the metabolic and genetic basis of known and previously unknown leukodystrophies is constantly increasing, opening new treatment options such as enzyme replacement or cell-based therapies. This brief review highlights some recent work, particularly emphasizing results from studies in adulthood leukodystrophies. Evidence from recent studies suggests increasing importance of metabolic dysfunctions, for example, in peroxisomal lipid metabolism or energy homeostasis, influencing axonal integrity and oligodendrocyte function and leading to white matter demyelination. In addition, diagnostic and therapeutic progress in metachromatic leukodystrophy, X-linked adrenoleukodystrophy, Krabbe diseases and other rare leukodystrophies with late onset are summarized. Better understanding of leukodystrophies in neurological routine practice is of crucial importance for differentiating between other white matter diseases such as toxic, inflammatory or vascular leukoencephalopathies. Many leukodystrophies are particularly important to recognize because specific treatments already exist or are currently under investigation. The article also provides an overview of currently known leukodystrophies in adulthood.
- 1 June 2010
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 23 (3) , 234-241
Leukodystrophies with late disease onset: an update
Knowledge of the metabolic and genetic basis of known and previously unknown leukodystrophies is constantly increasing, opening new treatment options such as enzyme replacement or cell-based therapies. This brief review highlights some recent work, particularly emphasizing results from studies in adulthood leukodystrophies. Evidence from recent studies suggests increasing importance of metabolic dysfunctions, for example, in peroxisomal lipid metabolism or energy homeostasis, influencing axonal integrity and oligodendrocyte function and leading to white matter demyelination. In addition, diagnostic and therapeutic progress in metachromatic leukodystrophy, X-linked adrenoleukodystrophy, Krabbe diseases and other rare leukodystrophies with late onset are summarized. Better understanding of leukodystrophies in neurological routine practice is of crucial importance for differentiating between other white matter diseases such as toxic, inflammatory or vascular leukoencephalopathies. Many leukodystrophies are particularly important to recognize because specific treatments already exist or are currently under investigation. The article also provides an overview of currently known leukodystrophies in adulthood.
- 27 June 2009
- Published by Springer Nature in Der Nervenarzt
- Vol. 80 (S1) , 16-17
Psychoedukatives Training für Patienten mit Multipler Sklerose
- 27 June 2009
- Published by Springer Nature in Der Nervenarzt
- Vol. 80 (S1) , 16-17
Psychoedukatives Training für Patienten mit Multipler Sklerose
- 1 December 2008
- Published by Springer Nature in Journal of Neurology
- Vol. 255 (S6) , 123-126
Diagnostic algorithm for the differentiation of leukodystrophies in early MS
Leukodystrophies are chronic progressive inherited white matter diseases frequently combined with an inborn error of metabolism. Some leukodystrophies clinically resemble chronic variants of multiple sclerosis (MS), while others exhibit multifocal MRI changes mimicking white matter changes known from MS imaging studies. The risk of misdiagnosing leukodystrophy as being MS is especially high in early disease stages comprising the possibility of initiating an inadequate therapy. Patients with clinical isolated syndromes should carefully be screened for positive family history, atypical clinical presentation or MRI pattern, symmetric involvement of long spinal tracts and peripheral nerves using evoked potentials and nerve conduction velocities and lack of oligoclonal bands in CSF all of which are “red flags” which consecutively may implicate consideration of leukodystrophy. Genetic or biochemical testing is widely available giving rise to a specific diagnosis in most patients.
- 1 December 2008
- Published by Springer Nature in Journal of Neurology
- Vol. 255 (S6) , 123-126
Diagnostic algorithm for the differentiation of leukodystrophies in early MS
Leukodystrophies are chronic progressive inherited white matter diseases frequently combined with an inborn error of metabolism. Some leukodystrophies clinically resemble chronic variants of multiple sclerosis (MS), while others exhibit multifocal MRI changes mimicking white matter changes known from MS imaging studies. The risk of misdiagnosing leukodystrophy as being MS is especially high in early disease stages comprising the possibility of initiating an inadequate therapy. Patients with clinical isolated syndromes should carefully be screened for positive family history, atypical clinical presentation or MRI pattern, symmetric involvement of long spinal tracts and peripheral nerves using evoked potentials and nerve conduction velocities and lack of oligoclonal bands in CSF all of which are “red flags” which consecutively may implicate consideration of leukodystrophy. Genetic or biochemical testing is widely available giving rise to a specific diagnosis in most patients.
- 1 May 2007
- Published by Springer Nature in Journal of Neurology
- Vol. 254 (2) , II90-II92
Psychosocial aspects in patients with myasthenia gravis
Myasthenia gravis patients usually present with fluctuating, asymmetrical stress-dependent weakness in the absence of other neurological disturbances. In weak patients psychopathological disturbances are frequently reported and misdiagnosed as a psychiatric disorder. The question to what extent psychiatric symptoms are involved in MG is still open. The case report presented here shows exemplary that psychopathological disturbances in exacerbated myasthenic patients are temporary and completely reversible after adequate somatic therapy.
- 1 May 2007
- Published by Springer Nature in Journal of Neurology
- Vol. 254 (2) , II90-II92
Psychosocial aspects in patients with myasthenia gravis
Myasthenia gravis patients usually present with fluctuating, asymmetrical stress-dependent weakness in the absence of other neurological disturbances. In weak patients psychopathological disturbances are frequently reported and misdiagnosed as a psychiatric disorder. The question to what extent psychiatric symptoms are involved in MG is still open. The case report presented here shows exemplary that psychopathological disturbances in exacerbated myasthenic patients are temporary and completely reversible after adequate somatic therapy.